Aurora-based GelSana Therapeutics secures a new funding of undisclosed amount.Mines Venture Fund participated in the round, which was led by Innosphere Ventures Fund.
With $3.1 million in non-dilutive and diluted funding acquired, GelSana plans to use the funds to advance its initial product towards the clinical market and offer a remedy for wounds that are challenging to heal.
Read also – San Francisco-based Every.io Secures $9.5M in Seed Funding
GelSana’s cutting-edge hydrogel technology, which blends materials with anti-inflammatory properties as well as controlled drug delivery capabilities, distinguishes it from its rivals. Furthermore, GelSana’s elastic hydrogels are ideal for a variety of wound care applications due to their extraordinary capacity to stretch and self-heal.
Under the leadership of CEO Melissa Krebs, GelSana is developing hydrogel technology, moving its initial product, Cleragel, closer to early clinical use and FDA approval. With its exclusive hydrogel technology, wound care becomes more efficient and economical by minimising the need for repeated applications and providing prolonged drug administration in an anti-inflammatory environment.
Read also- NYC-based Hang Secures $9.2M in Series A Round Funding
Meaningful progress has already been achieved by GelSana, which includes obtaining several grants and awards for their creative work, licencing intellectual property from the Colorado School of Mines, and finishing important animal experiments demonstrating the hydrogel’s improved ability to cure diabetic wounds.
About GelSana
GelSana biomaterials company, situated in Colorado, is creating innovative solutions that promote faster wound healing. We are developing the first hydrogel wound dressing that is somewhat sticky and able to disperse medication for a longer amount of time.
Read also – Washington-based Nanochon Secure an Investment from Cultivate(MD) Capital Funds
